Faslodex fulvestrant: Phase III started

AstraZeneca began the double-blind, placebo-controlled, international Phase III FALCON trial to compare 500 mg intramuscular Faslodex on days 0, 14 and 28 followed by every 28 days thereafter vs. 1 mg...